Physician
Urology
Dr. James A. Simon, MD
|
|
Give Review
James Simon works in the field of Urology. He attended Saint Louis University School of Medicine. Saint Louis University School of Medicine has a rank of 67 in research and a 57 in primary care Doctor James A. Simon, MD is a published doctor and has 101 publications published. The lastest was: 'Serum fatty acids and the risk of fatal cancer. MRFIT Research Group. Multiple Risk Factor Intervention Trial.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
- Current issues and available options in combined hormonal contraception.
- Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen.
- Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
- Current overview of the management of urogenital atrophy in women with breast cancer.
- Implementing a successful clinical development program for female sexual dysfunctions (aka how to navigate a regulatory minefield).
- Future developments in the medical treatment of abnormal uterine bleeding: what can we expect?
- The evolutionary origin and significance of menopause.
- Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen.
- Postmenopausal hormone therapy: risks versus benefits reassessed.
- Low sexual desire--is it all in her head? Pathophysiology, diagnosis, and treatment of hypoactive sexual desire disorder.
- Endometrial safety of ultra-low-dose estradiol vaginal tablets.
- The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation.
- Are all bisphosphonates the same? Potential reasons for clinical differences: a perspective.
- Vulvovaginal atrophy: current and future therapies (CME).
- The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
- Opportunities for intervention in HSDD.
- Postmenopausal estrogen therapy: which route to take?
- Understanding the menopausal experiences of professional women.
- Vulvovaginal atrophy: new and upcoming approaches.
- Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet.
- Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovagin...
- The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
- Testosterone therapy for sexual dysfunction in postmenopausal women.
- Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
- Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen.
- Testosterone therapy in women: its role in the management of hypoactive sexual desire disorder.
- Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial.
- Estradiol topical emulsion for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.
- Lifelong menstrual histories are typically erratic and trending: a taxonomy.
- Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in luteinizing hormone and follicle-stimulating hormone with age.
- Economic burden of endometriosis.
- Health-related quality of life burden of women with endometriosis: a literature review.
- The length of perimenopausal menstrual cycles increases later and to a greater degree than previously reported.
- Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, contr...
- Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
- Skeletal consequences of hormone therapy discontinuance: a systematic review.
- Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder.
- Does osteopenia warrant treatment?
- Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in steroid hormones and menstrual cycle lengths with age.
- Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.
- Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis.
- A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms.
- Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS).
- In vitro effect of gonadotropin-releasing hormone agonist on natural killer cell cytolysis in women with and without endometriosis.
- Treatment of osteoporosis: combination therapies.
- Counseling patients who elect to discontinue hormone therapy.
- Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial.
- Prevention and management of osteoporosis.
- Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine es...
- A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users.
- Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study.
- Maximizing health in menopausal women with disabilities.
- Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment.
- Estrogen replacement therapy: effects on the endogenous androgen milieu.
- MR imaging of diffuse adenomyosis changes after GnRH analog therapy.
- Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement ...
- Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease.
- Relation of ascorbic acid to bone mineral density and self-reported fractures among US adults.
- Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl...
- Relation of serum ascorbic acid to mortality among US adults.
- Safety of estrogen/androgen regimens.
- Perimenopausal women in estrogen vasomotor trials: contribution to placebo effect and efficacy outcome.
- Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS).
- Surgically induced endometriosis attenuates accrual of bone mineral density in growing rats.
- Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study.
- Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.
- Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause.
- Serum ascorbic acid and gallbladder disease prevalence among US adults: the Third National Health and Nutrition Examination Survey (NHANES III).
- Correlates of high HDL cholesterol among women with coronary heart disease.
- Does "white coat hypertension" increase the risk for any adverse outcome from hypertension?
- Serum ascorbic acid and other correlates of self-reported cataract among older Americans.
- Serum ascorbic acid and cardiovascular disease prevalence in U.S. adults: the Third National Health and Nutrition Examination Survey (NHANES III).
- Relationship of ascorbic acid to blood lead levels.
- Relation of serum ascorbic acid to serum vitamin B12, serum ferritin, and kidney stones in US adults.
- Pregnancy-specific glycoprotein gene expression in recurrent aborters: a potential correlation to interleukin-10 expression.
- Progestogens in the treatment of secondary amenorrhea.
- Serum fatty acids and the risk of fatal cancer. MRFIT Research Group. Multiple Risk Factor Intervention Trial.
- Serum ascorbic acid and other correlates of gallbladder disease among US adults.
- Relation of serum ascorbic acid to serum lipids and lipoproteins in US adults.
- Serum ascorbic acid and cardiovascular disease prevalence in U.S. adults.
- Ascorbic acid supplement use and the prevalence of gallbladder disease. Heart & Estrogen-Progestin Replacement Study (HERS) Research Group.
- Androgen effects on the central nervous system in the postmenopausal woman.
- Intracranial neurenteric cysts: a differential diagnosis and review.
- The relation of smoking to waist-to-hip ratio and diabetes mellitus among elderly women.
- Smoking cessation after surgery. A randomized trial.
- Relation of smoking and alcohol consumption to serum fatty acids.
- Serum fatty acids and blood pressure.
- Correlates of high-density lipoprotein cholesterol in Black girls and White girls: the NHLBI Growth and Health Study.
- Micronized progesterone: vaginal and oral uses.
- Serum fatty acids and the risk of coronary heart disease.
- The nonsurgical diagnosis of adenomyosis.
- Serum fatty acids and the risk of stroke.
- Adenomyosis: evidence for genetic cause.
- Familial adenomyosis: a case report.
- Adenomyosis: prospective comparison of MR imaging and transvaginal sonography.
- Dietary cation intake and blood pressure in black girls and white girls.
- Income and racial patterns of dietary vitamin C intake among black and white girls.
- The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone.
- Leuprolide acetate and bone mineral density measured by quantitative digitized radiography.
Schools
Saint Louis University School Of Medicine
Washington University In St Louis Urology
Washington University In St Louis General Surgery
Northwestern University
Procedures Preformed
- Bladder Repair Surgery
- Bladder Surgery
- Circumcision
- Complete Nephrectomy With Robotic Assistance
- View All
Doctors Specialties
- Urology
Accepted Insurances
Education
-
Washington University -
Washington University - Barnes-Jewish Hospital -
Saint Louis University School of Medicine
Drug Facts
| NPI NUMBER | 1447259171 | |
| NPPES Provider LastName | SIMON | |
| NPPES Provider FirstName | JAMES | |
| NPPES Provider ZIPCode | 809103151 | |
| NPPES Provider State | CO | |
| Specialty Description | Urology | |
| Total Claim Count | 801.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 35.0 | |
| Percent Opioid Claims | 4.37 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1447259171 |
| Last Name Of The Provider | SIMON |
| First Name Of The Provider | JAMES |
| View All |
Similar Doctors
|
Dr. Bruce L. Reimers, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Gary W. Bong, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jeffrey K. Ferguson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jerome P. Limoge Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jeffrey A. Moody, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jon E. Derksen, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael M. Crissey, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Henry M. Rosevear, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Richard A. Walsh, MD |
|
Dr. James R. Thomasch, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Nicholas J. Toepfer, MD
This Doctor is OpenDoctor Recommended.
|